SCHEMBL11900568

SCHEMBL11900568

CC(C)(C)OC(=O)N1CC(Nc2cc(F)ccc2[N+](=O)[O-])C1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC2 Q92769 2/20 0.44
ALDH1A1 P00352 4/20 0.43
LMNA P02545 1/20 0.43
CCNT1 O60563 1/20 0.41
CDK9 P50750 1/20 0.41
MAPK1 P28482 2/20 0.39
USP30 Q70CQ3 2/20 0.39
NPC1 O15118 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
BACE1 P56817 3/20 0.38
BACE2 Q9Y5Z0 2/20 0.38
EHMT2 Q96KQ7 1/20 0.38
GPR119 Q8TDV5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16657351 0.91 MAPT (0.47) MAPTHDAC1HDAC2ALDH1A1LMNA
SCHEMBL22716682 0.89 ALDH1A1 (0.53) MAPTALDH1A1LMNACCNT1CDK9
SCHEMBL15342504 0.87 USP30 (0.45) MAPTALDH1A1LMNAMAPK1USP30
SCHEMBL29848343 0.85 HPGD (0.46) MAPTALDH1A1LMNAGAA
SCHEMBL20571460 0.84 GPR119 (0.45) MAPTALDH1A1LMNAL3MBTL1GPR119
SCHEMBL16657349 0.84 ALDH1A1 (0.46) MAPTALDH1A1LMNAMAPK1USP30
SCHEMBL9986511 0.83 GPR119 (0.43) MAPTHDAC1HDAC2ALDH1A1LMNA
SCHEMBL9986508 0.83 GPR119 (0.43) MAPTHDAC1HDAC2ALDH1A1LMNA
SCHEMBL28695865 0.83 USP30 (0.42) MAPTHDAC1HDAC2ALDH1A1LMNA
SCHEMBL11901842 0.82 HDAC2 (0.60) MAPTHDAC1HDAC2ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
EP-2673269-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2013-12-18 EP disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 WO disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 WO disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 MAPT 1752/4885HDAC1 698/4885HDAC2 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.